Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 35 analyst ratings
Buy
Strong Buy 29%
Buy 26%
Hold 34%
Sell 9%
Strong Sell 3%

Bulls say

Amgen's financial outlook appears robust due to substantial sales growth from its flagship product Tavneos, which saw a remarkable 81% increase in the fourth quarter of 2024, contributing to overall U.S. sales of approximately $716 million in 2022, following a label expansion. The acquisition of Horizon Therapeutics has strengthened the company’s portfolio by adding several rare-disease treatments, including Tepezza, further enhancing its growth prospects alongside a strong emerging pipeline that includes promising candidates like Olpasiran and Imdelltra. Moreover, Amgen's strong cash position, coupled with a well-diversified product portfolio across key therapeutic areas, supports sustained long-term growth potential and reinforces the company's status as a high-quality player in the biotechnology sector.

Bears say

Amgen faces significant risks that may negatively impact its financial outlook, primarily due to heightened competition within its core business franchise, which could lead to market share erosion and increased pricing pressure. Additionally, the company is experiencing challenges related to lower-than-expected uptake for its newer products and potential regulatory setbacks for its late-stage pipeline and biosimilars. Looking ahead, management anticipates a potential mid-single-digit decline in pricing for its cholesterol-lowering drug, Repatha, which may further strain revenue growth as the competitive landscape evolves.

Amgen (AMGN) has been analyzed by 35 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 26% recommend Buy, 34% suggest Holding, 9% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Buy based on their latest research and market trends.

According to 35 analysts, Amgen (AMGN) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $285.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $285.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.